The opening post describes the usual case. This is about the unusual one. Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments might be needed.
On the subject in the title: Clearance pathways and what renal impairment changes Working notes rather than a conclusion.
What changes if the standard account of Clearance pathways is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
The opening post describes the usual case. This is about the unusual one.
Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments might be needed.
I have three months of notes on Clearance pathways and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
On post #4 — agreed on the reasoning, with one qualification.
Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number.
Old habit: I write down the expected answer before I calculate it.
Moving an injection by a day changes the concentration-time profile very little at these half-lives. It can change when somebody notices symptoms, which is a different and real thing.
Renal impairment changes clearance for some compounds in this class and not others, and the published data is compound-specific rather than class-wide.
This follows post #6 rather than contradicting it.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
That is the practical version. The rigorous version is longer and says the same thing.
Noted, and I have changed what I was going to do on the strength of it.
I have no financial interest in anything named in this thread and I want to say so before I comment on Clearance pathways, because it is the sort of subject where it matters.
This settles it for me, at least until somebody posts a reason it should not.
The arithmetic in post #11 is right; the assumption feeding it is the part to check.
Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.
Adding the caveat now so it does not have to be extracted later.
I had written a reply contradicting post #11 and deleted it. Here is what survived.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
The failure mode on Clearance pathways is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Adding a reference point for Clearance pathways. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Coming back to post #15, because the follow-up matters more than the original answer.
Hepatic metabolism: the degree to which each compound is hepatically metabolised versus renally cleared is known but varies. Severe liver disease changes clearance.
I have separated what I observed from what I concluded, which does not always happen.
Post #19 is right about the mechanism and I think understates the practical bit.
The reason Clearance pathways keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
What would change my mind on Clearance pathways is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Same experience here, different supplier, so it is at least not unique to one of them.
Post #20 is right about the mechanism and I think understates the practical bit.
Half-life determines how quickly concentration approaches steady state and does not determine what the steady-state concentration is. Dose and clearance determine that.
Coming back to post #23, because the follow-up matters more than the original answer.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
I would rather this thread reach "we do not know" about Clearance pathways than reach a confident answer that nobody can support when asked.
On Clearance pathways, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Confirming post #24 from a second method, which matters more than confirming it from a second person.
A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Renal impairment changes clearance for some compounds in this class and not others, and the published data is compound-specific rather than class-wide.
Adding a source would improve this post and I do not have one to hand.
Building on post #28 rather than restating it.
Where the Clearance pathways reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.